Current and Novel Biologic Therapies for Patients with Asthma and Nasal Polyps
OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA(2024)
摘要
A substantial portion of asthma and nasal polyps (NPs) share a common pathogenesis, which includes type 2-mediated inflammation. Distinct endotypes and phenotypes characterizing asthma and chronic rhinosinusitis have been identified. With emerging evidence describing pathophysiology, novel targets for biologic monoclonal antibody treatments have been developed. There are currently six biologic therapies approved by the US Food and Drug Administration to treat asthma, including omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab, three of these-omalizumab, mepolizumab, and dupilumab-are also approved for NPs.
更多查看译文
关键词
Biologics,Asthma,Nasal polyps,Chronic rhinosinusitis,Th2-mediated inflammation,Endotypes,Phenotypes
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要